Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Weishuai Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9549-5020; OpenAlex author ID A5034247665. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 10

  1. Single-cell landscape reveals PLPP2 upregulation underlying radiotherapy resistance and immune microenvironment remodeling in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2026.103054↗
  2. Research on precision treatment of pancreatic cancer targeted by antibody-drug conjugates. First author DOI 10.5582/bst.2025.01271↗
  3. The role of APOBEC mutagenesis in the progression and therapeutic guidance of pancreatic cancer. Last author DOI 10.1016/j.ygeno.2025.111098↗
  4. Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer. First author DOI 10.1038/s41467-025-67197-3↗
  5. Metabolic and Immunological Implications of MME+CAF-Mediated Hypoxia Signaling in Pancreatic Cancer Progression: Therapeutic Insights and Translational Opportu… Co-author DOI 10.1186/s12575-024-00254-1↗
  6. CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent Mechanism. Co-author DOI 10.1002/advs.202206335↗
  7. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endopl… Co-author DOI 10.1186/s13046-023-02814-x↗
  8. Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.841819↗
  9. CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms. First author DOI 10.1016/j.canlet.2021.07.024↗
  10. Celiac Plexus Block After Stereotactic Body Radiotherapy Improves Pain Relief in Locally Advanced Pancreatic Cancer. Co-author DOI 10.2147/jpr.s247303↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jihui Hao · 6 shared papers, 2021–2026 · strength 1.10
  2. Chao Wu · 4 shared papers, 2023–2026 · strength 0.84
  3. Yongjie Xie · 4 shared papers, 2023–2025 · strength 0.78
  4. Chongbiao Huang · 4 shared papers, 2021–2025 · strength 0.58
  5. Xinyue Liu · 2 shared papers, 2025–2026 · strength 0.54
  6. Xiaozhou Yu · 3 shared papers, 2021–2025 · strength 0.50
  7. Shengnan Li · 3 shared papers, 2022–2025 · strength 0.47
  8. Yaoyao Zhou · 1 shared paper, 2026 · strength 0.32
  9. Yifei Wang · 1 shared paper, 2026 · strength 0.32
  10. Song Gao · 2 shared papers, 2021–2025 · strength 0.29
  11. Xiuchao Wang · 2 shared papers, 2021–2023 · strength 0.27
  12. Tiansuo Zhao · 2 shared papers, 2021–2022 · strength 0.26
  13. Weihao Zhang · 1 shared paper, 2025 · strength 0.25
  14. Bo Ni · 1 shared paper, 2025 · strength 0.25
  15. Bin Wang · 1 shared paper, 2024 · strength 0.20
  16. Zhanyu Pan · 1 shared paper, 2024 · strength 0.20
  17. Yiping Zou · 1 shared paper, 2025 · strength 0.18
  18. Jun Yu · 1 shared paper, 2025 · strength 0.18
  19. Yukuan Feng · 1 shared paper, 2025 · strength 0.18
  20. Chao Yang · 1 shared paper, 2025 · strength 0.18
  21. Chunhua She · 1 shared paper, 2023 · strength 0.16
  22. Chao Xu · 1 shared paper, 2023 · strength 0.16
  23. Chuntao Gao · 1 shared paper, 2022 · strength 0.15
  24. Bo Tang · 1 shared paper, 2023 · strength 0.14
  25. Peng Xie · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.